XML 38 R27.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value Measurements and Derivative Financial Instruments (Tables)
6 Months Ended
Jun. 30, 2016
Fair Value Disclosures [Abstract]  
Financial Liabilities Measured at Fair Value on Recurring Basis

The following table presents the Company’s financial liabilities measured at fair value on a recurring basis as of June 30, 2016 and December 31, 2015, at each hierarchical level:

 

     June 30, 2016      December 31, 2015  
     Total     Level 1      Level 2     Level 3      Total     Level 1      Level 2     Level 3  

Other long-term liabilities:

                   

Interest rate swaps

   $ (178   $ —         $ (178   $ —         $ (79   $ —         $ (79   $ —     
Schedule of Derivative Financial Instruments Designated as Cash Flow Hedges

The following table presents the notional amount, fair value and balance sheet classification of the Company’s derivative financial instruments designated as cash flow hedges as of June 31, 2016 and December, 31, 2015:

 

          Notional      Fair  
    

Balance Sheet Location

   Amount      Value  

At June 30, 2016:

        

Interest rate swaps

  

Other long-term liabilities

   $ 43,788       $ 178   

At December 31, 2015:

        

Interest rate swaps

  

Other long-term liabilities

   $ 44,827       $ 79   
Schedule of Gains and Losses Before Income Taxes Recognized on Interest Rate Swaps Designated as Cash Flow Hedges

The following table presents gains and losses before income taxes on the Company’s interest rate swaps designated as cash flow hedges for the three and six-month periods ending June 30, 2016 and 2015:

 

     Three Months Ended      Six Months Ended  
     June 30,      June 30,  
     2016      2015      2016      2015  

(Loss) gain recognized in accumulated other comprehensive loss

   $ (49    $ 198       $ (174    $ 397   

(Loss) gain reclassified from accumulated other comprehensive loss (effective portion)

     (26      10         (53      1,970   

Gain recognized in interest expense (ineffective portion and amount excluded from effectiveness testing)

     —           274         —           541